POT- 4 inhibits C3 - Dry AMD Intravitreal

POT-4 developed by Potentia Pharmaceutical (Potencia Pharmaceutical, inc., Louiseville) affects the body’s “complement” system. Inflammation plays a role in developing macular degeneration.

Eight complement proteins are associated with AMD and POT-4 affects C3.

The problem is that inflammation is useful in fighting infections.

If the complement system is completely shut down, there is an increase risk for the development of bacterial infection.

Potentia has completed a phase I trial for POT-4 (called ASap) in patients with wet AMD.

The trial was designed to determine the safety and tolerability of an intravitreal injection of POT-4, as well as its stability and depot-forming properties.

In the study investigators observed only minimal and mild local adverse events related to the injection with no serious adverse events related to the drug itself^{(53, 54)}.